Uridine rescue from the lethal toxicity of 5-fluorouracil in mice
- PMID: 6178524
- DOI: 10.1007/BF00292865
Uridine rescue from the lethal toxicity of 5-fluorouracil in mice
Abstract
To determine the relationship between 5-fluorouracil (FUra) toxicity and its RNA- and DNA-directed actions we examined the ability of continuous SC infusions with uridine (Urd), thymidine (dThd), or deoxyuridine (dUrd) to rescue mice from the lethal toxicity of FUra. Male B6D2F1 mice were treated with a single IP injection of FUra (800 mg/kg) followed in 24 h by a 5-day infusion with either 0.9% NaCl or Urd (0.1, 1, 5, or 10 g/kg/day). Survivors were then followed up for 30 days after FUra treatment. Urd (1, 5, or 10 g/kg/day) rescued mice from the lethal toxicity of FUra, whereas Urd (0.1 g/kg/day) was as ineffective as 0.9% NaCl as a rescue agent. With variable doses of FUra followed in 24 h by a Urd infusion (5 g/kg/day) for 5 days. Urd rescued mice treated with FUra (400, 600, or 800 mg/kg) but was ineffective against higher doses of FUra (1,000 or 1,200 mg/kg). Mice treated with FUra (800 mg/kg) followed in 24 h by a 5-day infusion with either dThd (1, 5, or 10 g/kg/day) or a dUrd (1 or 5 g/kg/day) could not be rescued from the lethal toxicity of FUra. In all experiments deaths occurred between 6 and 12 days after FUra. These results, which demonstrate a specificity for Urd, but not for either dThd or dUrd, for rescuing mice from the lethal toxicity of FUra, suggest the importance of the RNA- rather than the DNA-directed actions of FUra as a determinant of its toxicity in mice.
Similar articles
-
Use of uridine rescue to enhance the antitumor selectivity of 5-fluorouracil.Cancer Res. 1983 Jul;43(7):3182-6. Cancer Res. 1983. PMID: 6850628
-
Human tissues degrade uridine much less than thymidine. Possible consequence for 5-fluorouracil therapy.Biochem Pharmacol. 1984 Mar 1;33(5):721-4. doi: 10.1016/0006-2952(84)90453-2. Biochem Pharmacol. 1984. PMID: 6712705
-
Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine.Cancer Chemother Pharmacol. 1989;24(1):9-14. doi: 10.1007/BF00254098. Cancer Chemother Pharmacol. 1989. PMID: 2720896
-
Modulation of 5-fluorouracil host-toxicity and chemotherapeutic efficacy against human colon tumors by 5-(Phenylthio)acyclouridine, a uridine phosphorylase inhibitor.Cancer Chemother Pharmacol. 2006 Nov;58(5):692-8. doi: 10.1007/s00280-006-0213-x. Epub 2006 Mar 10. Cancer Chemother Pharmacol. 2006. PMID: 16528530
-
Metabolism and mechanism of action of 5-fluorouracil.Pharmacol Ther. 1990;48(3):381-95. doi: 10.1016/0163-7258(90)90056-8. Pharmacol Ther. 1990. PMID: 1707544 Review.
Cited by
-
Limits to thymidylate synthase and TP53 genes as predictive determinants for fluoropyrimidine sensitivity and further evidence for RNA-based toxicity as a major influence.Cancer Res. 2009 Feb 1;69(3):984-91. doi: 10.1158/0008-5472.CAN-08-3610. Epub 2009 Jan 20. Cancer Res. 2009. PMID: 19155291 Free PMC article.
-
In vitro biochemical and in vivo biological studies of the uridine 'rescue' of 5-fluorouracil.Br J Cancer. 1988 Mar;57(3):259-65. doi: 10.1038/bjc.1988.56. Br J Cancer. 1988. PMID: 3355763 Free PMC article.
-
Uridine-induced hypothermia in mice and rats in relation to plasma and tissue levels of uridine and its metabolites.Cancer Chemother Pharmacol. 1987;20(2):101-8. doi: 10.1007/BF00253962. Cancer Chemother Pharmacol. 1987. PMID: 3664929
-
Tissue distribution of [18F]-5-fluorouracil in mice: effects of route of administration, strain, tumour and dose.Cancer Chemother Pharmacol. 1990;26(3):205-9. doi: 10.1007/BF02897200. Cancer Chemother Pharmacol. 1990. PMID: 2357768
-
Liquid Chromatography Mass Spectrometry-Based Metabolite Pathway Analyses of Myeloma and Non-Hodgkin's Lymphoma Patients.Cell J. 2017 Spring;19(Suppl 1):44-54. doi: 10.22074/cellj.2017.4412. Epub 2017 May 17. Cell J. 2017. PMID: 28580307 Free PMC article.